As an investor in the biotech sector, I understand the concerns about the lack of a deal within six months post the capital raise and the request for a placement resolution at the AGM. In my experience, the development and deal-making processes in this industry often take considerable time, primarily due to the extensive research, regulatory hurdles, and detailed negotiations involved.
The capital raised recently was crucial for advancing our research, securing regulatory approvals, and enhancing the market appeal of our products.
These steps are foundational for attracting potential deals.
Furthermore, proposing a placement resolution at the AGM can be a strategic move for financial robustness, rather than a sign of no deals on the horizon.
It's about maintaining financial flexibility and strength during negotiations.
It's also important to remember that deal negotiations in our field are typically confidential, and their absence from public discourse doesn't imply that they aren't underway.
OSL Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)